Key terms
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest GILD news
Today
6:06am ET
Hold Rating on Gilead Sciences Amidst Q1 Revenue Shortfall and Acquisition Concerns
Apr 08
10:50pm ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
Apr 08
3:18pm ET
Fly Insider: Xilio, Aerovate among weekâs notable insider trades
Apr 02
7:12am ET
Nurix Therapeutics announces extension of collaboration with Gilead
Mar 28
8:49am ET
Gilead announces FDA approval for Vemlidy sNDA
Mar 28
7:22am ET
Gilead sees FY24 EPS reduction of 3c-4c from Xilio Therapeutics deal
Mar 28
7:13am ET
Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301
Mar 28
7:10am ET
Xilio to get $43.5M upfront in pact with Gilead to develop/commercialize XTX301
Mar 24
5:03am ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Mar 22
9:41am ET
Unusually active option classes on open March 22nd
Mar 22
9:32am ET
Gilead Sciences Bolsters Portfolio with CymaBay Acquisition
Mar 22
9:27am ET
Gilead completes acquisition of CymaBay
Mar 22
9:27am ET
Gilead says CymaBay deal to lower 2024 EPS by $3.35-$3.45
Mar 19
4:34pm ET
Gilead to contact other potential bidders in light of recent media reports
Mar 19
2:00am ET
Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Gilead Sciences (GILD)
Mar 15
12:03pm ET
JPMorgan biotech/pharma analysts hold an analyst/industry conference call
Mar 14
4:25pm ET
Kevin Lofton Retires from Gilead Sciences Board
Mar 13
6:50am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Incyte (INCY)
Mar 11
8:41am ET
Gilead announces expiration of HSR waiting period for CymbaBay tender offer
Mar 11
7:01am ET
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Crinetics Pharmaceuticals (CRNX)
Mar 08
7:47am ET
Merus price target raised to $52 from $44 at BofA
Mar 06
4:32pm ET
Gilead says Biktarvy demonstrates high rates of viral suppression
Mar 06
10:28am ET
Gilead, Merck announce Phase 2 data on islatravir-lenacapavir combination
Mar 06
8:15am ET
Merus to potentially receive $56M in deal with Gilead to discover antigens
Mar 06
8:12am ET
Gilead receives option to license novel trispecific therapeutics in Merus deal
Mar 06
8:10am ET
Merus to receive $56M upfront in deal with Gilead to discover antigens
Mar 05
4:38pm ET
Gilead says new data further support use of Veklury in Covid-19 hospitalizations
Mar 05
8:59am ET
Arcellx price target raised to $87 from $57 at Truist
Mar 05
8:59am ET
Arcellx price target raised to $87 from $57 at Truist
Mar 04
11:57am ET
Gilead price target lowered to $78 from $84 at Wells Fargo
Feb 29
7:52am ET
Arcellx price target raised to $77 from $65 at BofA
GILD Financials
Key terms
Ad Feedback
GILD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
GILD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range